V. Leb-Reichl

This information is current as 1-Specific Th 2 Cells Cells Suppress the Effector Function of Bet v Human TCR Transgenic Bet v 1-Specific Th 1

H. J. Kueng, A. Neunkirchner, K. Schmetterer, 2011 .

Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma

R. Greil, D. Strunk, J. Bauer, 2021, Journal for ImmunoTherapy of Cancer.

Extracellular Vesicles as Biomarkers for the Detection of a Tumor Marker Gene in Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.

J. Reichelt, J. Mellerio, J. Bauer, 2017, The Journal of investigative dermatology.

Evaluating a Targeted Cancer Therapy Approach Mediated by RNA trans-Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin Cancer

J. Reichelt, T. Kocher, J. Bauer, 2022, International journal of molecular sciences.

Human TCR Transgenic Bet v 1-Specific Th1 Cells Suppress the Effector Function of Bet v 1-Specific Th2 Cells

H. J. Kueng, A. Neunkirchner, K. Schmetterer, 2011, The Journal of Immunology.

Genetic restriction of antigen-presentation dictates allergic sensitization and disease in humanized mice

R. Valenta, L. Kenner, A. Neunkirchner, 2018, EBioMedicine.

Bet v 1-specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1-specific T-cell effector function in an activation-dependent manner.

A. Neunkirchner, K. Schmetterer, W. Pickl, 2011, The Journal of allergy and clinical immunology.

Linked in: the extracellular matrix network in tumour dissemination

C. Guttmann-Gruber, J. Piñón Hofbauer, V. Leb-Reichl, 2020, The British journal of dermatology.